Detail akcie ImmunCllr Therap Rg online

Business Summary: EOM Pharmaceutical Holdings, Inc., through its wholly owned subsidiary EOM Pharmaceuticals, Inc., is a clinical-stage biotechnology company. The Company is focused on developing drugs with the potential to transform therapeutic paradigms and improve quality of life in patients suffering from debilitating and sometimes deadly diseases. Its pipeline includes its lead compound EOM613, an investigational novel dynamically dual-acting immunomodulator. EOM613 is a peptide nucleic-acid solution with both anti-inflammatory and pro-inflammatory broad spectrum cytokine effects. Human cell culture studies demonstrate that EOM613 can suppress or stimulate monocytes and macrophages depending on the activation state and environment of those key immune cells, resulting in either further activation or suppression. Its pipeline also includes EOM147, an investigational, broad-spectrum aminosterol with an intracellular mechanism for the treatment of retinal diseases.
Financial Summary: BRIEF: For the three months ended 31 March 2022, Eom Pharmaceutical Holdings Inc revenues was not reported. Net loss decreased 22% to $785K. Lower net loss reflects Advertising Expense decrease of 89% to $40K (expense), Research and development decrease of 24% to $383K (expense). Basic Earnings per Share excluding Extraordinary Items remained flat at -$0.01.